CAUSE, EPIDEMIOLOGY, MODE OF TRANSMISSION AND MANAGEMENT OF COVID-19
Keywords:
COVID-19, CFR, 3 TC, TDF, SARAS-CoV-2Abstract
Corona virus is a pandemic disease according to WHO (World health organisation). COVID-19 is caused by acute respiratory syndrome coronaviruse2 (SARAS-CoV-2). Initially, COVID-19 was started in Wuhan, a central china in December, 2019. The CFR (case fatility rate) depend upon the availibity of health care, age and health problem with in the population. On 12 January 2020, the World Health Organization temporarily named the new virus as 2019 novel corona virus (2019‐nCoV). The sporadic outbreaks of new types of CoVs remind us that CoVs are severe threat to affect the global public health. According to WHO, 87,137 cases was confirmed across worldwide since the beginning of the epidemic. Out of these, 2977 (3.42%) have been fatal. About 92% (79,968) of the confirmed cases were recorded in China, where almost all the deaths were also recorded (2,873, 96.5%) It is highly likely that new CoVID outbreaks are unavoidable in the future due to changes of the climate, ecology and increased interactions of human with animals. Thus, there is an urgent need to develop effective therapies and vaccines against COVID-19. At present, there is no vaccine or antiviral treatment for human corona virus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. There are general methods, which include broad-spectrum antiviral drugs and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual corona viruses, are used to discover the pontential antiviral treatment of human pathogen corona virus. Antiviral drugs includes Lopinavir, Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drug, could be the drug treatment options for 2019-nCoV. Therefore, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.
References
I. Wang C, Horby P.W, Hayden FG, Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020 (20) 30185-30190.
II. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 2009 Jun;7(6):439-50
III. Miri, Seyyed Mohammad; Roozbeh, Fatemeh; Omrani Rad, Ali; Alavian, Seyed Moayed. "Panic of Buying Toilet Papers: A Historical Memory or a Horrible Truth? Systematic Review of Gastrointestinal Manifestations of COVID-19". 16 March 2020.
IV. . Coronavirus Outbreak. Available at: https://www.worldometers. info/coronavirus/. Accessed 23 march 2020
V. Richman D.D, Whitley R.J, Hayden F.G. Clinical Virology, 4th ed. Washington: ASM Press; 2016.
VI. Chan-Yeung M, Xu R.H. SARS: epidemiology. Respirology. 2003; 8–14.
VII. World Health Organization. Middle East respiratory syndrome coronavirus (MERS‐CoV) Respiratory Syndrome Coronavirus.16 Feb 2020.
VIII. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
IX. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020.
X. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J. Med. 2020.
XI. Kampf, G, Todt D, P. faender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020 Feb 6.
XII. World Health Organization. Situation reports. Available at: https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/ situation-reports/. Accessed 22 Feb 2020.
XIII. Chen, H, Guo, J, Wang, C. etal. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: are trospective review of medical records. Lancet. 2020.
XIV. Coronavirus Outbreak. Available at: https://www.worldometers. info/coronavirus/. Accessed 23 Feb 2020.
XV. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.30 march 2016: 1-18.
XVI. . Zumla A, Chan J.F, Azhar E.I, Hui D.S, Yuen K.Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15:327-47.
XVII. National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection. January 23, 2020.
XVIII. Chu C.M, Cheng V.C, Hung I.F, Wong M.M, Chan K.H, Chan K.S, Kao R.Y, Poon L.L, Wong C.L, Guan Y, Peiris J.S, Yuen K.Y; HKU/UCH SARS Study Group.. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax. 2004; 59: 252256.
XIX. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERSCoV. Nat Commun. 2020 ; 11:222.
XX. Agostini M.L, Andres E.L, Sims A.C, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. M Bio. 2018; 9: 221-228.
XXI. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng C.K, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019; 5:4580.
XXII. Coleman C.M, Sisk J.M, Mingo R.M, Nelson E.A, White JM2, Frieman M.B. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016; 90:8924-8933.
XXIII. Ji S, Bai Q, Wu X, Zhang D.W, Wang S, Shen J.L, Fei G.H. Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother. 2020;121: 109652..
XXIV. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, Cheng PL, Yutao W, Zheng J, Yang Z, Zhang F. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17:130
XXV. Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med. 2020.
XXVI. Li J, Li J, Xie X, et al. Game consumption and the 2019 novel coronavirus. Lancet Infect Dis. 2020.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.
